Clinical overview of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with Type 2 diabetes mellitus

ISSN： 1744-6651

Source： Expert Review of Endocrinology and Metabolism, Vol.8, Iss.1, 2013-01, pp. : 21-35

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Linagliptin: A Novel Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor for Treatment of Type II Diabetes Mellitus

Current Diabetes Reviews, Vol. 7, Iss. 5, 2011-09 ,pp. : 325-335

Bentham Science Publishers

Access to resources Recommend Favorite

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus

By Raz I. Hanefeld M. Xu L. Caria C. Williams-Herman D. Khatami H.

Diabetologia, Vol. 49, Iss. 11, 2006-11 ,pp. : 2564-2571

Springer Publishing Company

Access to resources Recommend Favorite

Acute onset of rheumatoid arthritis associated with administration of a dipeptidyl peptidase-4 (DPP-4) inhibitor to patients with diabetes mellitus

By Sasaki Takashi

Diabetology International, Vol. 1, Iss. 2, 2010-12 ,pp. : 90-92

Springer Publishing Company

Access to resources Recommend Favorite

Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients

Current Vascular Pharmacology, Vol. 14, Iss. 6, 2016-10 ,pp. : 552-562

Bentham Science Publishers

Access to resources Recommend Favorite

Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials

Current Diabetes Reviews, Vol. 13, Iss. 4, 2017-07 ,pp. : 405-423

Bentham Science Publishers

Access to resources Recommend Favorite